Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study.

Pepijn W A ThomasNathan den BroederMonique DerikxWietske KievitRachel L WestMaurice G V M RusselJeroen M JansenTessa E H RömkensFrank Hoentjen

Published in: Inflammatory bowel diseases (2022)

Work impairment in IBD patients decreased following biological therapy or tofacitinib initiation. Patients achieving clinical remission or response showed the greatest improvement, especially UC and IBD-U patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
rheumatoid arthritis
prognostic factors
stem cells
bone marrow
mesenchymal stem cells
ulcerative colitis
patient reported